Plasma Cell Neoplasms (Including Multiple Myeloma) Research
MGUS to Myeloma: Study Suggests Risk of Progression Can ChangePosted:
A person’s risk of progressing from a benign condition called monoclonal gammopathy of undetermined significance (MGUS) to the blood cancer multiple myeloma can change over time, according to a new study.
Drug Shows Promise in Slowing Progression of Smoldering Myeloma to CancerPosted:
The drug lenalidomide (Revlimid) may delay the progression of smoldering myeloma to multiple myeloma, according to preliminary results from a clinical trial.
CAR T Cells: Expanding into Multiple MyelomaPosted:
Results from two early-phase trials presented at the American Society of Clinical Oncology annual meeting suggest that an immunotherapy using genetically engineered immune cells may be effective in patients with advanced multiple myeloma.
FDA Approves New Use for Lenalidomide in Multiple MyelomaPosted:
The FDA has approved lenalidomide for use as a maintenance therapy in patients with multiple myeloma who have undergone an autologous stem cell transplant, to help keep the cancer from coming back.
Three-Drug Combination Extends Survival for Patients with Multiple MyelomaPosted:
A phase III clinical trial demonstrates that adding the drug bortezomib to a commonly used two-drug regimen extends survival in patients with newly diagnosed multiple myeloma.
Daratumumab Improves Progression-Free Survival for Patients with Multiple MyelomaPosted:
Results from a phase III trial showed that adding daratumumab to lenalidomide and dexamethasone improved progression-free survival among patients with relapsed or refractory disease, compared with lenalidomide and dexamethasone alone.
Single Tumor Cells Reveal Clues to Biology of Multiple MyelomaPosted:
A study suggests that individual tumor cells circulating in the blood of patients with multiple myeloma may be a new source of information about the genetic changes driving the disease.
FDA Approves New Use for Daratumumab in Multiple MyelomaPosted:
The FDA has approved daratumumab, in combination with either of two other standard therapies, in patients with multiple myeloma whose disease has progressed after only a single prior treatment course.
Three New Therapies Approved for Multiple MyelomaPosted:
In November 2015, the FDA approved three new therapies for patients with multiple myeloma.
FDA Approves Expanded Indication for Carfilzomib in Patients with Multiple MyelomaPosted:
The FDA has approved carfilzomib in combination with other anticancer drugs to treat patients with relapsed multiple myeloma.
Three-Drug Combination Benefits Some Patients with Relapsed Multiple MyelomaPosted:
Interim results from an international, randomized phase III trial suggest that adding carfilzomib (Kyprolis®) to a standard treatment improves outcomes for patients with multiple myeloma whose cancer has relapsed. Participants in the study who received carfilzomib plus lenalidomide (Revlimid®) and dexamethasone lived a median of 8.7 months longer without the disease getting worse than patients who received lenalidomide and dexamethasone alone.
Pomalidomide plus Low-Dose Dexamethasone Improves Survival for Patients with Multiple MyelomaPosted:
Results from a randomized phase III trial show that the combination of pomalidomide (Pomalyst®) and low-dose dexamethasone may benefit some patients with multiple myeloma that has progressed (worsened) despite other treatments. Patients who received the combination therapy lived longer without the disease getting worse than patients who received high-dose dexamethasone alone. Overall survival was also improved in the group that received the combination therapy compared with the other group.